Benefit‐risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|67|2|482-491

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.67, Iss.2, 2018-02, pp. : 482-491

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effectiveness of sofosbuvir‐based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 5, 2015-09 ,pp. : 559-573

John Wiley & Sons Inc

Access to resources Recommend Favorite

Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 2, 2018-02 ,pp. : 134-143

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. 3, 2018-03 ,pp. : 443-450

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient with decompensated hepatitis C virus–related cirrhosis delisted for liver transplantation after successful sofosbuvir‐based treatment

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 3, 2015-03 ,pp. : 408-409

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

By  

HEPATOLOGY, Vol. 61, Iss. 6, 2015-06 ,pp. : 1793-1797

John Wiley & Sons Inc

Access to resources Recommend Favorite